OTEZLA® is available on the RxHelpTM ONE program. The program covers up to the difference in cost between OTEZLA® and its generic alternative(s)*
* Available in select provinces only. Refers to drug acquisition cost and reasonable markup. Dispensing fees not covered. Program can end at the manufacturer’s discretion.
an oral tablet for the
treatment of adult active
psoriatic arthritis
Demonstrated efficacy in active
psoriatic arthritis clinical
trials1,8,9
- ACR20 response at week 16 with OTEZLA 30 mg BID:
38% vs. placebo: 19%, p ≤ 0.01 (n=168 for both;
primary endpoint) - No evidence of attenuation of efficacy on ACR20
was seen for up to 52 weeks (uncontrolled from
weeks 24–52)
Simplicity of oral dosing1†
Proven safety profile1
-
Most common adverse reactions (≥ 5%) were
diarrhea (16.7%), nausea (15.3%), and headache
(10.5%), which were mostly mild to moderate in
intensity.* Incidences of these adverse events were
higher in females than in males
* More than half of these adverse events resolved within the first 30 days.1
† OTEZLA is administered 30 mg BID after initial titration. Please consult the Product Monograph for complete dosage and administration instructions, including dose adjustments in patients with severe renal impairment (CrCl < 30 mL/min).1
ACR, American College of Rheumatology; BID, twice daily; CrCl, creatinine clearance; MOA, mechanism of action; PsA, psoriatic arthritis; PsO, psoriasis.